WATERTOWN, Mass., Sept. 28, 2020 /PRNewswire/ -- Arranta Bio
("Arranta"), the leading microbiome contract development and
manufacturing organization (CDMO), today announced the mechanical
completion of GMP suites at its Watertown, MA commercial-ready facility.
Arranta is investing more than $100M in 2020 to establish a state of the art,
multi-product, commercial-ready manufacturing facility that will
supply live biotherapeutic products (LBPs) to microbiome innovator
companies. The Watertown facility
has been designed to the highest specifications for advanced
biologics production.
"We are grateful to the Arranta team and to our construction
management partner, DC Beane and Associates Construction Company,
who specializes in the construction and development of life science
facilities, and the numerous sub-contractors who have supported
Arranta and worked through the pandemic in a safe and efficient
manner to keep our commercial-ready manufacturing facility
build-out on schedule. This is a remarkable accomplishment that
will enable Arranta to supply vital products to patients in need
and provide more than 200 new product development, manufacturing
and operations jobs," Mark Bamforth,
President and CEO of Arranta Bio, said.
Arranta is also expanding process development, and GMP capacity
at its early-clinical supply facility in Gainesville, FL. Learn more about overcoming
the construction management challenges during the pandemic by
registering for a webinar moderated by Arranta's co-founder,
Iain Baird, taking place on
Wednesday Sept 30th at
10am EST at
https://kineticos.com/building-a-cdmo-facility-during-covid
About 200 companies are actively exploring the linkage between
diseases and the microbiome – millions of bacteria, fungi, protozoa
and viruses that live inside and on the human body – in order to
identify therapeutic targets. Scientists have called the microbiome
the second genome; in fact, the number of genes in the microbes
making up one person's microbiome is estimated to be at least 200
times the number in the human genome.
In the past decade, the industry has experienced a rapid
acceleration in scientific understanding of the composition and
functions of gut microbiota. Arranta is proud to be the leading
CDMO focused on supporting the supply needs of these innovator
companies.
About Arranta Bio
Founded in 2019, Arranta Bio is a
contract development and manufacturing organization (CDMO)
specifically established to focus on serving companies seeking to
develop and commercialize therapies targeting the human microbiome.
In November 2019, Arranta Bio
acquired Captozyme™ – the leader in process development
and clinical contract manufacturing for microbiome pioneers – whose
experienced team has worked with and developed processes for over
135 different species spanning 85 different genera of live
biotherapeutics since 2009. Headed by a management team and
technical experts with a proven track record in both process
development and contract manufacturing through fermentation to
lyophilization and encapsulation of live biopharmaceuticals,
Arranta Bio offers the knowledge and resources necessary to help
clients develop and manufacture promising new microbiome therapies
and plasmids to meet the needs of patients. Additional information
about Arranta Bio is available at www.arrantabio.com.
Arranta Bio Media contact:
Guy Tiene
That's Nice LLC
T: +1 212 366 4455
E: guy@thatsnice.com
Arranta Bio Services contact:
Use
info@arrantabio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arranta-bio-announces-mechanical-completion-of-commercial-ready-capacity-for-advanced-biologics-301138714.html
SOURCE Arranta Bio